| Gastric Adenocarcinoma
Herceptin vs Trazimera
Side-by-side clinical, coverage, and cost comparison for gastric adenocarcinoma.Deep comparison between: Herceptin vs Trazimera with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTrazimera has a higher rate of injection site reactions vs Herceptin based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trazimera but not Herceptin, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Herceptin
Trazimera
At A Glance
IV infusion
Weekly or every 3 weeks
HER2 antagonist
IV infusion
Weekly or every 3 weeks
HER2/neu receptor antagonist
Indications
- Malignant neoplasm of breast
- Gastric Adenocarcinoma
- Adenocarcinoma of the gastroesophageal junction
- Breast Carcinoma
- Gastric Adenocarcinoma
- Adenocarcinoma of the gastroesophageal junction
Dosing
Malignant neoplasm of breast (adjuvant) Schedule 1: 4 mg/kg loading dose over 90 min IV, then 2 mg/kg weekly over 30 min for 12 or 18 weeks, then 6 mg/kg every 3 weeks to complete 52 weeks; Schedule 2: 8 mg/kg loading dose over 90 min IV, then 6 mg/kg every 3 weeks for 52 weeks.
Malignant neoplasm of breast (metastatic) 4 mg/kg loading dose as 90-min IV infusion, then 2 mg/kg weekly as 30-min IV infusions until disease progression.
Gastric Adenocarcinoma, Adenocarcinoma of the gastroesophageal junction 8 mg/kg loading dose over 90-min IV infusion, then 6 mg/kg over 30-90 min IV every 3 weeks until disease progression, in combination with cisplatin and capecitabine or 5-fluorouracil.
Breast Carcinoma (adjuvant) 4 mg/kg loading dose over 90 min IV, then 2 mg/kg weekly for 12-18 weeks, then 6 mg/kg IV q3w to complete 52 weeks total; alternatively, 8 mg/kg loading dose over 90 min IV, then 6 mg/kg IV q3w for 52 weeks.
Breast Carcinoma (metastatic) 4 mg/kg loading dose over 90 min IV, then 2 mg/kg weekly IV until disease progression.
Gastric Adenocarcinoma, Adenocarcinoma of the gastroesophageal junction 8 mg/kg loading dose over 90 min IV, then 6 mg/kg IV over 30-90 min q3w until disease progression.
Contraindications
—
—
Adverse Reactions
Most common Fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, myalgia
Serious Cardiomyopathy, infusion reactions, embryo-fetal toxicity, pulmonary toxicity, exacerbation of chemotherapy-induced neutropenia
Postmarketing Infusion reaction, oligohydramnios, glomerulopathy, immune thrombocytopenia, tumor lysis syndrome
Most common Fever, nausea, vomiting, infusion reactions, diarrhea, infections, increased cough, headache, fatigue, dyspnea, rash, neutropenia, anemia, myalgia
Serious Cardiomyopathy, severe infusion reactions, pulmonary toxicity, embryo-fetal toxicity, exacerbation of chemotherapy-induced neutropenia
Postmarketing Infusion reaction, oligohydramnios or oligohydramnios sequence, glomerulopathy, immune thrombocytopenia, tumor lysis syndrome
Pharmacology
Humanized IgG1 kappa monoclonal antibody (anti-HER2) that inhibits proliferation of HER2-overexpressing tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) preferentially on HER2-overexpressing cancer cells.
Trastuzumab-qyyp is a HER2/neu receptor antagonist that inhibits proliferation of HER2-overexpressing human tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) preferentially on HER2-overexpressing cancer cells compared with cells that do not overexpress HER2.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Herceptin
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (1/12) · Qty limit (0/12)
Trazimera
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Herceptin
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Trazimera
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Herceptin
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Trazimera
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Herceptin.
$0/fillfill
Trazimera Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HerceptinView full Herceptin profile
TrazimeraView full Trazimera profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.